Madam Speaker, I am grateful for the opportunity to speak today on this motion and, in particular, to talk about some of the good work being done by the government to address this health issue.
With the aging of the population, more people will develop Alzheimer's disease or related dementia. The number of Canadians afflicted is expected to rise substantially over the next 30 years, with the aging of the baby boomer population and the health needs that go along with it.
I am firmly of the view that it is through investments and research that we can unlock the potential to lessen the burden of Alzheimer's and dementia, not just on individuals and families, but also on the health system.
Let me offer one example. It has been estimated that delaying the onset of Alzheimer's and dementia by only two years would reduce its cumulative costs over the next 30 years by an estimated $219 billion. Delaying onset by two years would reduce the number of cases in Canada by 410,000.
That is the promise. However, we will see that promise realized only through research breakthroughs. That is why I am proud to say that through the Canadian Institutes of Health Research, the government has invested over $88 million in research into the causes, treatments and potential cures for Alzheimer's disease and related dementia since 2006, including $22.7 million in 2009 and 2010 alone.
Through these investments, Canadian researchers in this field are recognized around the world for their excellence. Federal research funding facilitates their efforts in discovering ways to prevent, diagnose and treat this devastating illness.
Our investments include CIHR's commitment of $2.5 million over five years for the Canadian Dementia Knowledge Translation Network, which will share information about dementia with a wide range of players in our health care system. What is more, CIHR is investing $30 million in the Canadian Longitudinal Study on Aging, investigating neuropsychological, social and economic issues of Canadians aged 45 to 85 over the next 20 years.
CIHR, like many funding organizations worldwide, has recognized there is a global imperative to act on the rising tide of Alzheimer's disease and related dementia. That is why it has recently established the international collaborative research strategy for Alzheimer's disease. The international strategy will encourage scientific collaborations between researchers in Canada and other researchers around the world.
The objective is to establish joint funding partnerships, which will address the growing national and international issue. This international strategy recognizes that presently treatment that follows a diagnosis of Alzheimer's or dementia occurs too late in the course of the underlying disease after permanent damage to brain cells has already occurred.
Therefore, the international strategy's research agenda will focus on the early events in Alzheimer's and dementia. In doing so, experts will examine research problems that are biomedical and clinical as related to health services. Social, cultural and environmental influences on population health will also be examined. The goal is to identify the disease early so that measures can be put in place to delay its onset.
CIHR is working closely with the Alzheimer's Society of Canada in putting together this international strategy. Our government has already signed several international agreements and funding initiatives with France, the U.K. and Germany, which will work with us to combat this global health problem.
Additional partnerships are being developed with China, Belgium and the U.S. All of this work and leadership on behalf of our government will be a huge asset to the provinces and territories in the delivery of their health care system.
The motion asks for the recognition of the important role played by civil society organizations, such as the Alzheimer's Society of Canada, in advancing our understanding of Alzheimer's and dementia. In addition to the partnerships mentioned above, I am pleased to note that CIHR is working closely with the Alzheimer's Society of Canada through its Institute of Aging.
A program called the cognitive impairment in aging partnership has invested $32 million to date in linking researchers and key stakeholders to advance strategic research and knowledge translation on cognitive impairment and dementia.
With investments in world-class research excellence, Canada has built a number of distinct global advantages: an excellent track record in Alzheimer's and dementia research; a reputation for high impact research; and CIHR's strong reputation for partnership and innovation in health research.
Canada is fortunate to be an ideal site for clinical trials and large population-based studies such as the Canadian longitudinal study on aging. Our expertise and resources will enable us to be poised to develop a better understanding of the risk factors around Alzheimer's and dementia, particularly regarding genetics, nutrition and lifestyle.
I expect the future will bring promising developments in early diagnosis with new findings in genomics, diagnostic biomarkers, brain imaging and psychological and cognitive testing. I am hopeful that these findings will lead to new approaches in early intervention with therapeutic clinical trials with a focus on prevention.
We will learn how the control of blood pressure and cholesterol, exercise, nutrition, mental stimulation and aspects of our social environment can impact on this disease. Our goal is to prevent and mitigate the toll of Alzheimer's and dementia on individuals and society by leveraging our track record in research and galvanizing the Canadian research community by building partnerships with users of research knowledge and mobilizing coordinated and innovative international research efforts.
I am confident that we will make substantial progress to this goal. I would like to thank the member for Edmonton—Leduc for his hard work in bringing this forward today.